U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07951034) titled 'A Study of HER2-Targeted Antibody-Drug Conjugates Compared With Hormone-Based Therapy for Hormone Receptor-Positive, HER2-Low Metastatic Breast Cancer' on Oct. 20.
Brief Summary: This phase 3 study will compare anti-HER2 antibody-drug conjugate treatment with hormone-receptor-directed treatment in women with endocrine therapy-resistant, hormone receptor-positive, HER2-low metastatic breast cancer. Participants are assigned at random in a 1:1 ratio to one of the two treatment groups. The primary objective is to compare progression-free survival. Other planned assessments include overall survival, tumor response, adverse events, and p...